Evidence map›Paper›PMID 29371107›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018

Advance Directive Utilization Is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

Kathryn Cappell, Vandana Sundaram, Annie Park, Parveen Shiraz, Ridhi Gupta, Patricia Jenkins, Vyjeyanthi S J Periyakoil, Lori Muffly

Open access · hybridAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kathryn CappellDepartment of Medicine, Blood and Marrow Transplantation, Stanford University, Stanford, California.
Vandana SundaramQuantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, California.
Annie ParkDepartment of Hematology/Oncology, Kaiser Permanente, Santa Clara, California.
Parveen ShirazDepartment of Hematology/Oncology, Kaiser Permanente, Santa Clara, California.
Ridhi GuptaDepartment of Medicine, Blood and Marrow Transplantation, Stanford University, Stanford, California.
Patricia JenkinsDepartment of Medicine, Blood and Marrow Transplantation, Stanford University, Stanford, California.
Vyjeyanthi S J PeriyakoilDepartment of Medicine, Palliative Care, Stanford University, Stanford, California.
Lori MufflyDepartment of Medicine, Blood and Marrow Transplantation, Stanford University, Stanford, California. Electronic address: lmuffly@stanford.edu.
Stanford University · USKaiser Permanente Santa Clara Medical Center · USStanford Blood Center · US

Funding

TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3M
Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
TLI/ATG CONDTIONING: KIDNEY/BLOOD STEM CELL TRANSPLANTSP01HL075462 · NHLBI · STANFORD UNIVERSITY · PI ENGLEMAN, EDGAR G. · 2004 to 2020
$27.9M
Trial of strategies to communicate genetic information to different ethnic and racial subpopulationsU54MD010724 · NIMHD · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD · 2016 to 2021
$16.3M
Working Memory in Parkinson Disease: A Cognitive & Systems Neuroscience ApproachP50AG047366 · NIA · STANFORD UNIVERSITY · PI HENDERSON, VICTOR · 2015 to 2019
$7.9M
Stanford Medicine Center for Longevity and Healthy Aging Research Education CoreP30AG059307 · NIA · STANFORD UNIVERSITY · PI ZOU, JAMES · 2018 to 2025
$4.9M
Palliative care needs and outcomes for dementia patientsR01AG062239 · NIA · STANFORD UNIVERSITY · PI PERIYAKOIL, VYJEYANTHI S · 2018 to 2023
$3.7M
In-reach for Successful Aging through Education(i-SAGE)R25MD006857 · NIMHD · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI PERIYAKOIL, VYJEYANTHI S · 2011 to 2015
$1.7M
NCI NIH HHS P01 CA049605NCI NIH HHS P30 CA124435NHLBI NIH HHS P01 HL075462NIA NIH HHS P30 AG059307NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG062239NIMHD NIH HHS R25 MD006857NIMHD NIH HHS U54 MD010724
6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is associated with significant morbidity and mortality, making advance care planning (ACP) and management especially important in this patient population. A paucity of data exists on the utilization of ACP among allogeneic HCT recipients and the relationship between ACP and intensity of healthcare utilization in these patients. We performed a retrospective review of patients receiving allogeneic HCT at our institution from 2008 to 2015 who had subsequently died after HCT. Documentation and timing of advance directive (AD) completion were abstracted from the electronic medical record. Outcomes of interest included use of intensive care unit (ICU) level of care at any time point after HCT, within 30 days of death, and within 14 days of death; use of mechanical ventilation at any time after HCT; and location of death. Univariate logistic regression was performed to explore associations between AD completion and each outcome. Of the 1031 patients who received allogeneic HCT during the study period, 422 decedents (41%) were included in the analysis. Forty-four percent had AD documentation prior to death. Most patients (69%) indicated that if terminally ill, they did not wish to be subjected to life-prolonging treatment attempts. Race/ethnicity was significantly associated with AD documentation, with non-Hispanic white patients documenting ADs more frequently (51%) compared with Hispanic (22%) or Asian patients (35%; P = .0007). Patients with ADs were less likely to use the ICU during the transplant course (41% for patients with ADs versus 52% of patients without ADs; P = .03) and also were less likely to receive mechanical ventilation at any point after transplantation (21% versus 37%, P < .001). AD documentation was also associated with decreased ICU use at the end of life; relative to patients without ADs, patients with ADs were more likely to die at home or in hospital as opposed to in the ICU (odds ratio, .44; 95% confidence interval, .27 to .72). ACP remains underused in allogeneic HCT. Adoption of a systematic practice to standardize AD documentation as part of allogeneic HCT planning has the potential to significantly reduce ICU use and mechanical ventilation while improving quality of care at end of life in HCT recipients.

Indexed as

Advance DirectivesAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansIntensive Care UnitsMaleMiddle AgedRespiration, ArtificialRetrospective StudiesTerminal CareTransplantation, HomologousAdvance care planningAdvance directiveAllogeneic hematopoietic stem cell transplantationEnd-of-life careLeukemia

Identifiers

PMID29371107
PMCPMC6364975
OpenAlexW2785001416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.